Verition Fund Management
KYTX icon

Verition Fund Management’s Kyverna Therapeutics KYTX Stock Holding History

Verition Fund Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-90,235
Closed -$337K – 3768
2024
Q4 		$337K Buy
90,235
+45,609
+102% +$219K ﹤0.01% 2712
2024
Q3 		$218K Buy
+44,626
New +$344K ﹤0.01% 2828

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return

Verition Fund Management's KYTX Position: Q1 2025 in Review

Verition Fund Management sold out of Kyverna Therapeutics (KYTX) in Q1 2025, closing a stake of 90,235 shares — an estimated $337K sold.

Verition Fund Management first reported a position in KYTX in Q3 2024 and held it in 2 quarters. The position peaked at $337K in Q4 2024. 87 funds tracked by Wall St. Rank hold KYTX as of Q1 2025.

  • Verition Fund Management reported no remaining Kyverna Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 90,235 Kyverna Therapeutics shares in Q1 2025, an estimated $337K.
  • Verition Fund Management first reported a position in Kyverna Therapeutics in Q3 2024 and held it in 2 quarters.
  • Verition Fund Management's Kyverna Therapeutics position peaked at $337K in Q4 2024.
  • 87 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.